Guillermo Orti

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: January 14, 2026

Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT.

Management of tyrosine kinase inhibitors and donor lymphocyte infusions post transplantation for chronic myeloid leukemia: a survey of contemporary practice on behalf of the chronic malignancies working party of the EBMT.

Journal: Bone marrow transplantation

Published: November 16, 2025

Incidence, clinical risk factors, and biomarkers of SOS/VOD following allogeneic HSCT in adults. A real-life study by the Spanish group of HSCT and cell therapy (GETH-TC).

Incidence, clinical risk factors, and biomarkers of SOS/VOD following allogeneic HSCT in adults. A real-life study by the Spanish group of HSCT and cell therapy (GETH-TC).

Journal: Bone marrow transplantation

Published: October 02, 2025

Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation.

Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation.

Journal: Cancers

Published: August 20, 2025

One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.

One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.

Journal: Annals of hematology

Published: August 14, 2025

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Journal: Transplantation and cellular therapy

Published: May 19, 2025

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Haploidentical Donor versus Mismatched Unrelated Donor in Reduced-Intensity Conditioning Stem Cell Transplantation: A GETH-TC Study.

Journal: Transplantation and cellular therapy

Published: May 19, 2025

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.

Journal: Blood advances

Published: February 25, 2025

Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC.

Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC.

Journal: Frontiers in immunology

Published: February 05, 2025

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Journal: The Lancet. Oncology

Published: November 07, 2024

Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.

Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.

Journal: Bone marrow transplantation

Published: October 28, 2024

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study.

Journal: Leukemia

Published: September 04, 2024

Showing 1-12 of 53

Last Updated: 09/26/2026